Inhibrx Biosciences (INBX) Market Update
- Closing price (23 Feb 2026): USD 97.1
- Price movement: Up 3.03 % during the 24‑hour period ending at 01:21 AM CET on Friday, 23 Feb 2026.
- Shares outstanding: 14.7 million.
- Market capitalization: USD 1.4 billion.
- Trading volume (last 24 h): USD 23.5 million.
- Performance since prior month‑end: Down 11.28 %.
- 200‑day simple moving average: USD 91.8.
- 52‑week high: USD 155.29 (22 Apr 2026).
- 52‑week low: USD 46.01 (24 Oct 2025).
Comparative Performance of Peer Stocks (Last 24 h)
| Ticker | Current price | % change | Market cap | Additional note |
|---|---|---|---|---|
| WLTH (Wealthfront) | USD 11.20 | +1.78 % | USD 1.7 bn | – |
| KLRA (Kailera Therapeutics) | USD 13.27 | +0.23 % | USD 1.7 bn | – |
| AMN (Amn Healthcare Services) | USD 46.82 | +3.34 % | USD 1.7 bn | P/E ratio: 20.52 |
| KMTS (Kestra Medical) | USD 28.32 | –3.43 % | USD 1.7 bn | – |
| NUVB (Nuvation Bio) | USD 4.70 | +1.68 % | USD 1.7 bn | – |
Summary
Inhibrx Biosciences experienced a moderate rise in share price during the reported 24‑hour window, bringing its valuation to USD 1.4 billion with a trading volume of USD 23.5 million. The stock’s performance contrasts with a broader decline of 11.28 % since the end of the previous month. Key technical indicators, such as the 200‑day simple moving average (USD 91.8) and 52‑week extremes, provide context for the current price level. Peer companies in the biotechnology and healthcare sectors displayed mixed movements, with Amn Healthcare Services leading gains at +3.34 % and Kestra Medical experiencing a decline of –3.43 %.
